{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T10:11:13Z","timestamp":1771323073740,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"DOI":"10.1038\/s41390-026-04820-z","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T09:20:23Z","timestamp":1771320023000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cross-border access to clinical trials: participation of pediatric patients and language inclusion"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4494-3663","authenticated-orcid":false,"given":"Begonya","family":"Nafria","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4209-1142","authenticated-orcid":false,"given":"Joana","family":"Claverol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4630-1576","authenticated-orcid":false,"given":"Marta","family":"Cubells","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Llanos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Sol\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisenda","family":"Sans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2152-8579","authenticated-orcid":false,"given":"Jaume","family":"Catala-Mora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5658-1831","authenticated-orcid":false,"given":"Susana","family":"Rives","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0592-673X","authenticated-orcid":false,"given":"Andr\u00e9s","family":"Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merc\u00e8","family":"Pineda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9853-688X","authenticated-orcid":false,"given":"\u00c0ngels","family":"Garc\u00eda Cazorla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4952-5732","authenticated-orcid":false,"given":"Andr\u00e9s","family":"Nascimento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8370-0883","authenticated-orcid":false,"given":"Marta","family":"Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Roe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Fortuny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4938-9673","authenticated-orcid":false,"given":"Bob","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"4820_CR1","unstructured":"DIRECTIVE 2011\/24\/EU OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 9 March 2011 on the application of patients\u2019 rights in cross-border healthcare. https:\/\/eur-lex.europa.eu\/eli\/dir\/2011\/24\/oj. Accessed 21 February 2025."},{"key":"4820_CR2","unstructured":"Regulation (EU) No 536\/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001\/20\/EC. https:\/\/eur-lex.europa.eu\/eli\/reg\/2014\/536\/oj. Accessed 21 February 2025."},{"key":"4820_CR3","unstructured":"Charter of Fundamental Rights of the European Union (18.12.2000) Official Journal of the European Communities. C364\/9. https:\/\/www.europarl.europa.eu\/charter\/pdf\/text_en.pdf. Accessed 21 February 2025."},{"key":"4820_CR4","doi-asserted-by":"publisher","first-page":"e1003758","DOI":"10.1371\/journal.pmed.1003758","volume":"18","author":"AV Muthukumar","year":"2021","unstructured":"Muthukumar, A. V., Morrell, W. & Bierer, B. E. Evaluating the frequency of English language requirements in clinical trial eligibility criteria: a systematic analysis using ClinicalTrials. gov. PLoS Med. 18, e1003758 (2021).","journal-title":"PLoS Med."},{"key":"4820_CR5","doi-asserted-by":"publisher","unstructured":"Ruiz, J. et al. Achieving language justice in pediatric hematology-oncology: a multinational perspective for language-concordant equitable patient- and family-centered care and research inclusion. Pediatr. Blood Cancer e31521. https:\/\/doi.org\/10.1002\/pbc.31521 (2025).","DOI":"10.1002\/pbc.31521"},{"key":"4820_CR6","doi-asserted-by":"publisher","unstructured":"Muthukumar, A. V. et al. Persistent exclusion of non-English speakers in Pediatric research: a national analysis using ClinicalTrials.gov. Pediatr. Res. https:\/\/doi.org\/10.1038\/s41390-025-03845-0 (2025).","DOI":"10.1038\/s41390-025-03845-0"},{"key":"4820_CR7","unstructured":"Accelerating Clinical Trials in the European Union (ACT EU) initiative. https:\/\/accelerating-clinical-trials.europa.eu\/index_en. Accessed 21 February 2025."},{"key":"4820_CR8","unstructured":"Source: https:\/\/clinicaltrials.gov\/. Accessed 21 February 2025."},{"key":"4820_CR9","unstructured":"http:\/\/enprema.ema.europa.eu\/enprema\/. Accessed 21 February 2025."},{"key":"4820_CR10","unstructured":"Data reported by the Clinical Trials Unit at SJD Barcelona Children\u2019s Hospital on 27th of January, 2025. Data about the clinical trials conducted in 2024, reported in the internal management system."},{"key":"4820_CR11","unstructured":"Ley 14\/2007, de 3 de julio, de Investigaci\u00f3n biom\u00e9dica. \u00abBOE\u00bb n\u00fam. 159, de 4 de julio de 2007, 28826\u201328848. https:\/\/www.boe.es\/eli\/es\/l\/2007\/07\/03\/14. Accessed 21 February 2025."},{"key":"4820_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1441807","volume":"15","author":"S Vavassori","year":"2024","unstructured":"Vavassori, S., Russell, S., Scotti, C. & Benvenuti, S. Unlocking the full potential of rare disease drug development: exploring the not-for- profit sector\u2019s contributions to drug development and access. Front. Pharmacol. 15, 1441807 (2024).","journal-title":"Front. Pharmacol."},{"key":"4820_CR13","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/s43441-024-00638-1","volume":"58","author":"MJ Lamberti","year":"2024","unstructured":"Lamberti, M. J. et al. Benchmarking site activation and patient enrollment. Ther. Innov. Regul. Sci. 58, 696\u2013703 (2024).","journal-title":"Ther. Innov. Regul. Sci."},{"key":"4820_CR14","first-page":"103","volume":"11","author":"PM Wandile","year":"2023","unstructured":"Wandile, P. M. Patient recruitment in clinical trials: areas of challenges and success, a practical aspect at the private research site. J. Biosci. Med. 11, 103\u2013113 (2023).","journal-title":"J. Biosci. Med."},{"key":"4820_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-024-02698-8","volume":"13","author":"V Bencheva","year":"2024","unstructured":"Bencheva, V. et al. Barriers and facilitators to enrollment in pediatric clinical trials: an overview of systematic reviews. Syst. Rev. 13, 283 (2024).","journal-title":"Syst. Rev."},{"key":"4820_CR16","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/pedi.12465","volume":"18","author":"R Farrell","year":"2016","unstructured":"Farrell, R., Bethin, K., Klingensmith, G., Tamborlane, W. V. & Gubitosi-Klug, R. Barriers to participation in industry-sponsored clinical trials in pediatric type 2 diabetes. Pediatr. Diabetes 18, 574\u2013578 (2016).","journal-title":"Pediatr. Diabetes"},{"key":"4820_CR17","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1177\/2168479016632271","volume":"50","author":"KA Getz","year":"2016","unstructured":"Getz, K. A. et al. The impact of protocol amendments on clinical trial performance and cost. Ther. Innov. Regul. Sci. 50, 436\u2013441 (2016).","journal-title":"Ther. Innov. Regul. Sci."},{"key":"4820_CR18","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s43441-024-00667-w","volume":"58","author":"ZP Smith","year":"2024","unstructured":"Smith, Z. P., DiMasi, J. A. & Getz, K. A. New estimates on the cost of a delay day in drug development. Ther. Innov. Regul. Sci. 58, 855\u2013862 (2024).","journal-title":"Ther. Innov. Regul. Sci."},{"key":"4820_CR19","unstructured":"Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies Guidance for Industry DRAFT GUIDANCE- Food and Drug Administration. https:\/\/www.fda.gov\/media\/179593\/download. Accessed 21 February 2025."},{"key":"4820_CR20","unstructured":"Convention on the Rights of the Child, Nov. 20, 1989. https:\/\/www.unicef.org.uk\/wp-content\/uploads\/2016\/08\/unicef-convention-rights-child-uncrc.pdf. Accessed 21 February 2025."},{"key":"4820_CR21","unstructured":"Source: https:\/\/database.ich.org\/sites\/default\/files\/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106.pdf. Accessed 8 December 2025."},{"key":"4820_CR22","unstructured":"Source: https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki\/. Accessed 8 December 2025."},{"key":"4820_CR23","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ejca.2008.09.032","volume":"45","author":"A Bottomley","year":"2009","unstructured":"Bottomley, A., Jones, D. & Claassens, L. Patient-reported outcomes: assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency. Eur. J. Cancer 45, 347\u2013353 (2009).","journal-title":"Eur. J. Cancer"},{"key":"4820_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.968272","volume":"9","author":"MM Teixeira","year":"2022","unstructured":"Teixeira, M. M. et al. A review of patient-reported outcomes used for regulatory approval of oncology medicinal products in the European Union between 2017 and 2020. Front. Med. 9, 968272 (2022).","journal-title":"Front. Med."},{"key":"4820_CR25","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/j.1524-4733.2005.04054.x","volume":"8","author":"D Wild","year":"2005","unstructured":"Wild, D. et al. ISPOR Task Force for Translation and Cultural Adaptation. Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. Value Health 8, 94\u2013104 (2005).","journal-title":"Value Health"},{"key":"4820_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122685","volume":"348","author":"T Mohammadian Gol","year":"2024","unstructured":"Mohammadian Gol, T. et al. Gene therapy in pediatrics\u2014clinical studies and approved drugs (as of 2023). Life Sci. 348, 122685 (2024).","journal-title":"Life Sci."},{"key":"4820_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2024.1382190","volume":"11","author":"AK Moaveni","year":"2024","unstructured":"Moaveni, A. K. et al. Advances and challenges in gene therapy strategies for pediatric cancer: a comprehensive update. Front. Mol. Biosci. 11, 1382190 (2024).","journal-title":"Front. Mol. Biosci."}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-04820-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-04820-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-04820-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T09:20:26Z","timestamp":1771320026000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-04820-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":27,"alternative-id":["4820"],"URL":"https:\/\/doi.org\/10.1038\/s41390-026-04820-z","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"15 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}